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Older persons have higher autoimmunity but a lower prevalence of autoimmune diseases. A possible explanation
for this is the expansion of many protective regulatory mechanisms highly characteristic in the elderly. Of note is
the higher production of peripheral T-regulatory cells.
The frequent development of autoimmunity in the elderly was suggested to take place in part due to the selection
of T cells with increased affinity to self-antigens or to latent viruses. These cells were shown to have a greater ability
to be pro-inflammatory, thereby amplifying autoimmunity. During aging, thymic T-regulatory cell output decreases
in association with the loss of thymic capacity to generate new T cells. However, to balance the above mentioned
autoimmunity and prevent the development of autoimmune diseases, there is an age-related increase in peripheral
CD4+ CD25highFoxP3+ T-regulatory cells. It remains unclear whether this is an age-related immune dysfunction or
a defense response. Whatever the reason, the expansion of T-regulatory cells requires payment in terms of an
increased incidence of cancer and higher susceptibility to infections.
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Over the course of the human life, age-related diseases de-
velop because of the failure of genetic traits to remain
beneficial, as they were in younger years when they aided
in successful reproduction. Longevity is correlated with
optimal natural immunity. Immunosenescence (aging of
the immune system) is continuously influenced by chronic
antigenic stimulation, such as infections. This explains
why the probability of a long lifespan is improved in an
environment of reduced pathogen burden. In the presence
of low pathogen burden one can expect a balanced state
of immune responses and alter the chances of having ad-
vanced inflammatory responses [1].
In studies of aging, it has been noticed that the capacity
to cope with a variety of infections reduces over time, a
status that was identified as ‘inflamm-aging’. The persist-
ence of inflammatory stimuli over time serves as a ‘first
hit’, increasing susceptibility to age-related diseases. A ‘se-
cond hit’, the absence of robust beneficial gene variants, is
crucial in the development of advanced organ-specific
age-related diseases [2].
Although inflammation (via pro-inflammatory cytokines
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reproduction in any medium, provided the orneutralizing dangerous infectious agents in young people,
it becomes a meaningful stress leading to altered immuno-
regulatory and/or unbalanced responses in aged indivi-
duals. The later development of continuous organ damage
in the presence of altered or unbalanced immune responses
is responsible for the development of many age-related dis-
eases, including cardiovascular [3,4]. Among other diseases
that are age related are the increased prevalence of auto-
immunity, autoantibodies and cancers, and an increased
susceptibility to bacterial and viral infections. Here, we will
focus on some of these issues in relation to aging.Autoantibodies and aging
In one of the first studies dealing with the prevalence of
non-organ-specific antibodies in the elderly, it was found
that rheumatoid factor, antinuclear antibodies and anti-
cardiolipin antibodies were detected in 14%, 31% and 51%
(respectively) of healthy individuals over 80 years old, in
comparison to not more than 2% in the non-elderly popu-
lation [5]. Other studies have reported on the higher
prevalence of both organ- and non-organ-specific auto-
antibodies among healthy centenarians (age range 101 to
106 years) when compared with prevalence among youn-
ger individuals (age range 26 to 60 years). The main
increase was noticed in autoantibodies such as antinuclear
antibodies, anti-cardiolipin antibodies and anti-thyroidl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Increased T-regulatory cell function in the elderly balances increased autoimmunity but increases the incidence of cancer and
sepsis. (A) Autoantibodies are frequent in aged individuals because of increased tissue damage and apoptosis. (B) Aiming to balance this
increased autoimmunity, peripheral Tregs become enhanced, suppressing both CD4 and CD8 T cell function, allowing the development of
cancers and increasing susceptibility to infections. (C) Recurrent viral and bacterial infections stimulate pro-inflammatory cytokines, which are
further stimulated by this expansion of Tregs. (D) Treg expansion in the elderly is followed by the increase of T-helper 17 cells and the
persistence of chronic inflammation.
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to be the result of a damaged tissue process and high ex-
posure to apoptotic cells rather than an autoimmune
response [6]. These facts were further established when
various autoantibodies such as rheumatoid factor, antinu-
clear antibodies, anti-cardiolipin antibodies, antineutrophil
cytoplasmic antibodies and others were assessed in 276
people who celebrated their 100th birthday. Among these,
79% had at least one of the above mentioned antibodies. In
this study also, the high level of antibodies did not reflect a
similar high level of full-blown autoimmune disease [7].
The mechanisms and the meaning of autoimmunity
during aging is not clear. However, it looks as though
autoimmunity is only a reflection of the advanced organ
damage that takes place during aging and the resulting
immune response.
Autoimmune diseases in the elderly
In contrast to the frequent prevalence of autoantibodies
in the elderly, autoimmune diseases are rare. When they
exist, they are mild and well controlled with moderateimmunomodulatory therapies. When systemic lupus ery-
thematosus (SLE) was assessed in individuals over 65 -
years of age, the incidence of late-onset SLE ranged
between 12% and 18% and the course of the disease was
found to be milder. Skin manifestations, photosensitivity,
arthritis and nephritis were rarely reported. However,
lung involvement and Sjogren’s syndrome were observed
more frequently. In patients with late-onset SLE, one
can observe higher prevalence of autoantibodies such as
rheumatoid factor, anti-Ro and anti-cardiolipin anti-
bodies but a lower occurrence of hypocomplementemia
[8]. A possible explanation for this higher autoimmunity
but lower or milder autoimmune diseases is the expan-
sion of many protective regulatory mechanisms highly
characteristic in the elderly. Of note is the higher pro-
duction of protective natural immunoglobulin M auto-
antibodies, such as immunoglobulin M anti-cardiolipin
and immunoglobulin M anti-double stranded DNA anti-
bodies. All these autoantibodies have been reported to
play a role in preventing the development of severe SLE
and are higher in patients without renal disease [9].
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The frequent development of autoimmunity in the elderly
may occur in part due to the selection of T cells with in-
creased affinity to self-antigens or to latent viruses. These
T cells have been shown to have a greater ability to be
pro-inflammatory, thereby amplifying autoimmunity [10].
During aging, the output of thymic T-regulatory cells
(Tregs) decreases in association with the loss of thymic
capacity to generate new T cells. However, to balance the
above and prevent the development of autoimmune
diseases, there is an age-related increase in peripheral gen-
eration of CD4+ CD25highFoxP3+ Tregs. It remains un-
clear whether this is an immune dysfunction or a defense
response aiming to balance the increase in autoimmunity.
Whatever the reason, the expansion of Tregs requires pay-
ment in terms of an increased incidence of cancer and
higher susceptibility to infections [11].T-regulatory cells and cancer
Increased autoimmunity during aging has been explained
by many to be the result of Tregs, though expanded, fail-
ing to suppress auto-reactive T cells (in response to en-
hanced apoptosis). Although young and aged CD4+ Tregs
equally suppressed interferon-γ + T cells in a mouse
model, aged Tregs failed to restrain IL-17+ T cells during
inflammation, suggesting a chronic inflammation-related
defect in aged Tregs. The aged Tregs expressed reduced
STAT3 activation, a defect that was found to be in associ-
ation with poor IL-17-producing T cell restraint, which
may contribute to the development of autoimmunity in
the elderly [12]. By contrast, many studies have shown
that Tregs (both in animal models and humans) are ex-
panded in the elderly. This results in increased suppres-
sion of T cell immune responses and the prevention of
autoimmune diseases, but increases susceptibility to infec-
tious diseases and cancer, which become the leading
causes of morbidity and mortality in the elderly [13].
The role of immunosuppressive Tregs in tumor im-
mune evasion and metastatic spread is well established.
Therefore, one may assume that changes in numbers or
function of Tregs could lead to a higher incidence of
tumors in the elderly. Many studies have been designed
to assess this relationship. In one of these, the percen-
tage of and changes in FoxP3 expression in CD4 +
CD25highCD127low were analyzed in older people in
relation to the development of non-small cell lung can-
cer. The percentage of peripheral Tregs and the expres-
sion of FoxP3 mRNA were significantly increased in
elderly patients with non-small cell lung cancer com-
pared with healthy elderly and young individuals. The
percentage of Tregs and the expression of FoxP3 mRNA
were closely associated with tumor node metastasis sta-
ging in elderly patients with lung cancer [14].Tregs and sepsis
Inducible Tregs are important in keeping peripheral tole-
rance and in preventing CD4+ T cells from responding to
T cell receptor stimulation and entering the cell cycle.
One of these subsets is CD8 + CD45RA +C-C chemokine
receptor 7 (CCR7) + Foxp3 T cells, the suppressive activity
of which is independent of IL-10 and relies on interfe-
rence with very early steps of the T cell receptor signaling
cascade. The inducibility of CD8 +CCR7+ Tregs was
shown to be age related and their number in individuals
older than 60 years was much lower than in younger
people. Loss of CD8 + CCR7+ Tregs in the elderly host is
of relevance in the aging immune system because
immunosenescence is associated with a state of chronic
smoldering inflammation [15]. The status of Tregs in re-
spect to the beneficial immune response during sepsis has
also been assessed. In elderly patients, an increased per-
centage of circulating Tregs significantly correlated with a
decreased lymphoproliferative response. In a murine
model of sepsis mimicking these observations, the ex vivo
downregulation of FoxP3 expression using siRNA was as-
sociated with a restoration of this response [16].
Final comments
In the elderly, autoimmunity is balanced by the immune
response expanding the number of peripheral Tregs,
which prevents full-blown autoimmune diseases. This
natural process must remain tuned and reasonable,
otherwise CD4+ T effector cells or CD8 cytotoxic T cells
will be suppressed, allowing the development of cancers
and sepsis (see Figure 1). One of the future goals is to
determine how to affect this tuning, namely, how to
immunomodulate Tregs in the elderly.
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